Nasogastric/Orogastric Tube Placement Verification Study Using RightSpot pH Indicator to Verify Gastric Acidity
|ClinicalTrials.gov Identifier: NCT01561729|
Recruitment Status : Unknown
Verified November 2014 by RightBio Metrics.
Recruitment status was: Recruiting
First Posted : March 23, 2012
Last Update Posted : November 4, 2014
|Condition or disease||Intervention/treatment||Phase|
|Small Bowel Obstruction Gastrointestinal Hemorrhage||Device: RightSpot pH Indicator Radiation: Chest radiograph||Not Applicable|
To assess the level of accuracy of the RightSpot pH Indicator in determining correct placement of NG/OG tubes as compared to the gold standard of CXR in Emergency Department & ICU patients.
Hypothesis 1: In greater than 90% of the cases, RightSpot pH Indicator will be successful in confirming the placement of NG/OG tubes by demonstrating a pH of 4.5 or less in patients with CXR proven tube placement.
Hypothesis 2: The time to confirmation of NG/OG tube placement will be significantly less using the RightSpot pH Indicator than using CXR. The time will be calculated by the start time consisting of the time that the NG/OG tube was placed until the end time, which will be when the device pH Indicator testing is performed. The time to confirmation using the gold standard of a CXR will begin when the NG/OG tube is placed and end when the CXR is available on PACS (picture archiving and communication system).
To determine via subgroup analysis whether gross blood in the stomach, presence of acid-reducing medications, or trauma affects the accuracy of NG/OG placement determination by the RightSpot pH Indicator.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of RightBio Metrics', RightSpot pH Indicator, for Rapid Bedside Verification of Proper Nasogastric/ Orogastric Tube Placement in Emergency Department & Intensive Care Unit Patients|
|Study Start Date :||January 2012|
|Estimated Primary Completion Date :||December 2014|
|Estimated Study Completion Date :||December 2014|
Experimental: Study group
This is the only arm of the study. All patients enrolled will have a nasogastric or orogastric tube placed. All will be assessed by both the RightSpot pH Indicator and chest radiograph.
Device: RightSpot pH Indicator
The RightSpot pH Indicator device is used to confirm proper placement of all types of gastric tubes used for gastric rest, suction, or medicating/feeding by measuring the pH of stomach aspirate. This device is intended for 1 (one) SINGLE USE. The probability of proper placement is higher when the pH is less than or equal to 4.5 and if aspirate has a typical gastric fluid appearance (grassy green, brown, colorless- with possible shreds of off-white mucus or sediment).Radiation: Chest radiograph
Chest radiograph will be taken after tube placement to verify proper positioning of the nasogastric or orogastric tube.
Other Name: CXR
- Determination of proper placement of ng/og tube [ Time Frame: Participants will be followed until the determination of proper placement of the ng/og tube is made. This is anticipated to be less than 3 hours. ]The pH will be assessed by visual inspection of pH paper within the device. If the pH is noted to be less than 4.5 then the placement will be considered to be within the stomach.
- Confounding factors for using the RightSpot pH Indicator [ Time Frame: Participants will be followed until the determination of proper placement of the ng/og tube is made. This is anticipated to be less than 3 hours. ]A subgroup analysis will be done to determine whether gross blood in the stomach, presence of acid-reducing medications, or trauma affects the accuracy of NG/OG placement determination by the RightSpot pH Indicator.
- Time to confirmation of tube placement [ Time Frame: Participants will be followed until the determination of proper placement of the ng/og tube is made. This is anticipated to be less than 3 hours. ]The time to verification of tube placement will be measured for both chest radiograph and use of RightSpot pH Indicator.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01561729
|Contact: Jason Wilson, MD||(813)firstname.lastname@example.org|
|United States, Florida|
|Tampa General Hospital||Recruiting|
|Tampa, Florida, United States, 33606|
|Contact: Jason Wilson, MD 813-627-5937 email@example.com|
|Contact: Jennifer Nilsen, RN (813)844-3162 Jenniferanilsen@tgh.org|
|Principal Investigator:||Jason Wilson, MD||University of South Florida Emergency Medicine Residency Program|